Manasquan-based Exalenz Bioscience Ltd., a global developer of medical devices for gastrointestinal and liver diseases, announced Monday it has appointed Roy Golan as president and chief financial officer.
Golan will report to CEO Raffi Werner.
“We are pleased to welcome Roy to our leadership team in these exciting times at Exalenz,” Werner said. “Roy’s extensive history of successful financial leadership in the healthcare industry will be a key asset for Exalenz as we continue to grow and prepare for a listing on a major U.S. exchange later this year. His strong relationships within the healthcare financial community will advance the development and execution of our strategies for creating value for patients and investors and realizing our near-term product opportunities in the gastroenterology and hepatology markets.”
Golan has more than 18 years of experience in the health care and software industries, most recently serving as chief financial officer at NeuroDerm Ltd.
“I am pleased to join Exalenz at this exciting time and to be part of realizing the tremendous value of our products and technologies,” Golan said. “Exalenz is strongly positioned to transform the diagnosis, monitoring and management of serious gastrointestinal and liver diseases.”
